1st Quarter - Report

BUCHANAN INGERSOLL & ROONEY PC for LIPOCINE

Period 1st Quarter 2018 Filed Apr 20, 2018 Signed by Will Le

Official filing
Firm
BUCHANAN INGERSOLL & ROONEY PC
Client
LIPOCINE
Income
$20,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone.

LobbyistCovered position, as disclosed
TIMOTHY COSTA —
MICHAEL P STRAZZELLA —
ELIZABETH WESTBROOK —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Pharmacy PHA

Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone.

LobbyistCovered position, as disclosed
TIMOTHY COSTA —
MICHAEL P STRAZZELLA —
ELIZABETH WESTBROOK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone.

LobbyistCovered position, as disclosed
TIMOTHY COSTA —
MICHAEL P STRAZZELLA —
ELIZABETH WESTBROOK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.